Case Report: Telitacicept in severe myasthenia gravis: a case study with multiple autoantibodies

Qian Guo; Yusen Huang; Fangruyue Wang; Le Fang

doi:10.3389/fimmu.2023.1270011

Frontiers in Immunology (Dec 2023)

Case Report: Telitacicept in severe myasthenia gravis: a case study with multiple autoantibodies

Qian Guo,
Yusen Huang,
Fangruyue Wang,
Le Fang

Affiliations

Qian Guo: Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, China
Yusen Huang: Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, China
Fangruyue Wang: The Third Bethune Hospital of Jilin University, Changchun, China
Le Fang: Department of Neurology, China-Japan Union Hospital of Jilin University, Changchun, China

DOI: https://doi.org/10.3389/fimmu.2023.1270011
Journal volume & issue: Vol. 14

Abstract

Read online

Multi-antibody-positive myasthenia gravis (MG) presentations are relatively rare, often found in older patients, and generally predict a poor prognosis. We report a case of a female patient with generalized MG, testing positive for Titin antibodies (Titin-Ab), ryanodine receptor antibodies (RyR-Ab), and acetylcholine receptor antibodies (AChR-Ab), and resistant to acetylcholinesterase inhibitors. Following unsuccessful traditional therapies, she received Telitacicept, leading to significant improvements. This case underscores Telitacicept’s potential efficacy for similar patients and offers insights into the clinical characteristics of multi-antibody MG.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords